APA
Click to copy
O’Neill, M., Ma, J. G., Aldridge, J. L., Solus, J., Harvey, G. R., Roberson, P. H., … Ng, C.-A. (2025). Automated patch clamp data improve variant classification and penetrance stratification for SCN5A–Brugada syndrome. European Heart Journal.
Chicago/Turabian
Click to copy
O’Neill, M., Joanne G. Ma, Jessa L Aldridge, J. Solus, Genevieve R. Harvey, Paige H. Roberson, J. Barc, et al. “Automated Patch Clamp Data Improve Variant Classification and Penetrance Stratification for SCN5A–Brugada Syndrome.” European Heart Journal (2025).
MLA
Click to copy
O’Neill, M., et al. “Automated Patch Clamp Data Improve Variant Classification and Penetrance Stratification for SCN5A–Brugada Syndrome.” European Heart Journal, 2025.
BibTeX Click to copy
@article{m2025a,
title = {Automated patch clamp data improve variant classification and penetrance stratification for SCN5A–Brugada syndrome},
year = {2025},
journal = {European Heart Journal},
author = {O’Neill, M. and Ma, Joanne G. and Aldridge, Jessa L and Solus, J. and Harvey, Genevieve R. and Roberson, Paige H. and Barc, J. and Bezzina, C. and Roden, Dan M. and Walsh, Roddy and Vandenberg, Jamie I. and Glazer, A. and Ng, Chai-Ann}
}
Background and Aims Brugada Syndrome (BrS) is an inherited arrhythmia disorder that causes an elevated risk of sudden cardiac death. Approximately 20% of patients with BrS have rare variants in SCN5A, which encodes the cardiac sodium channel NaV1.5. Genetic workup of BrS is often complicated by SCN5A variants of uncertain significance (VUS) and/or incomplete penetrance. This study deployed an SCN5A-BrS functional assay at cohort scale to facilitate the implementation of genetic and precision medicine. Methods All 252 missense and in-frame insertion/deletion SCN5A variants from a previously published large cohort of BrS cases (n = 3335 patients) were analysed using a calibrated high-throughput automated patch-clamp (APC) assay. Variant functional Z-scores were assigned evidence levels ranging from BS3_moderate (normal function) to PS3_strong (loss-of-function), as defined by American College of Medical Genetics and Genomics criteria. Functional evidence was combined with population frequency, hotspot, case counts, protein-length changes, and in silico predictions. Odds ratios of BrS case–control enrichment and penetrance for BrS were calculated from variant frequencies in the BrS cohort and in gnomAD. Results Most variants (146/252) were functionally abnormal (Z ≤ −2), with 100 having severe loss-of-function (Z ≤ −4). Functional evidence enabled the reclassification of 110 of 225 VUS; 104 to likely pathogenic and 6 to likely benign. SCN5A variants with loss-of-function were mainly localized to the transmembrane domains, especially the regions comprising the central pore. SCN5A variant penetrance was proportional to the severity of loss-of-function; variants with Z ≤ −6 had penetrance of 24.5% (15.9%–37.7% CI) and an odds ratio of 501 for BrS. Conclusions This cohort-scale APC dataset stratifies SCN5A variants found in BrS patients into normal function ‘bystander’ variants that have a low risk of BrS and loss-of-function variants that have a high risk for BrS. Functional data can be integrated with other criteria to reclassify a substantial fraction of VUS. The dataset helps clarify the SCN5A–BrS relationship and will improve the diagnosis and clinical management of BrS probands and their families.